This pharma stock is trending today!
Shares of the company surged 14%.
On November 22, the market is trading in the green. At noon, the S&P BSE Sensex is trading flat at 61,334.03, up 0.3%, while NIFTY50 is trading flat at 18,216.05, up 0.3%. About sectoral performance, Commodities are outperforming, while Realty is among the top losers. Regarding stock-specific action, Kopran Ltd is the top gainer among BSE group ‘B’.
Shares of Kopran Ltd have surged 14% and are trading at Rs 154.8, as of noon. Yesterday, on November 21, the stock hit a fresh 52-week low of Rs 131.3. Today, the stock has recovered well. However, in the last 6 months, the stock was in a strong downtrend, falling more than 30%.
Kopran is an integrated pharmaceutical company, manufacturing international quality formulations and Active Pharmaceutical Ingredients (API). It is a major player in the manufacturing of Sterlite Cephalosporins. They also provide a range of speciality products including macrolides, anticonvulsants and a cardiovascular range of drugs among others.
Last week, on November 15, the company announced its September quarterly results. For the recent quarter Q2FY23, on a consolidated basis, the total revenue decreased 8.31% YoY to Rs 117 crore. The EBITDA fell sharply by 57.77% YoY and was reported at Rs 10.14 crore.
The company’s net profit also took a hit and registered a drop of 73% to come in at Rs 4.65 crore, as against Rs 17 crore in Q2FY22.
As per the FY22 period ending, the company has an ROE and ROCE of 18.2% and 21.4%, respectively.
About the shareholding pattern, 44.25% of the company’s stake is owned by the promoters, 0.51% by FIIs, 0.14% by DIIs, and the rest 55.09% by non-institutional investors.
The company has a market capitalisation of Rs 734 crore and is currently trading at a PE multiple of 14.7x. The stock has a 52-week high and low of Rs 369.35 and Rs 131.3, respectively.
Start Investing in 5 mins*
Rs. 20 Flat Per Order | 0% Brokerage
About the Author
DisclaimerInvestment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Open Free Demat Account
By proceeding, you agree to the T&C.
Fill in your details below: